📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
520 announcements match the current filters (relevance ≥ 5).
Thyrocare Recommends Rs 7 Dividend, Re-appoints CEO, and Invests Rs 5.5 Cr in Subsidiary
Thyrocare's board has recommended a final dividend of Rs 7.00 per share, bringing the total FY26 dividend to Rs 9.33 per share post-bonus adjustment. The company is re-appointing Rahul Franklin Guha as CMD & CEO for another five-year term and has approved a fresh investment of up to Rs 5.50 crore in its subsidiary, Think Health Diagnostics. Additionally, the company is broadening its Memorandum of Association to include a wider range of healthcare and digital diagnostic services. Significant board reshuffling also occurred with two resignations and two new appointments of non-executive directors.
Key Highlights
Recommended final dividend of Rs 7.00 per share; total FY26 dividend stands at Rs 9.33 post-bonus adjustment
Re-appointment of Rahul Franklin Guha as CMD & CEO for a 5-year term starting May 2027
Approved investment of up to Rs 5.50 crore in wholly-owned subsidiary Think Health Diagnostics Private Limited
Appointment of Price Waterhouse Chartered Accountants LLP as Statutory Auditors for a 5-year term
Proposed MOA changes to broaden business scope into digital platforms and allied healthcare services
👀 What to Watch
Investors should find the dividend payout and leadership continuity as positive indicators of stability. The strategic expansion of the business scope via MOA amendments suggests a long-term growth plan in the digital healthcare ecosystem.
Thyrocare Recommends ₹7 Final Dividend, Appoints PWC as Auditor, and Re-appoints CEO
Thyrocare Technologies has recommended a final dividend of ₹7.00 per share, bringing the total FY26 dividend to ₹9.33 per share post-bonus adjustment. The company is strengthening its governance by appointing Price Waterhouse Chartered Accountants LLP as statutory auditors for a five-year term. Leadership continuity is secured with the re-appointment of Rahul Franklin Guha as MD & CEO for another five years. Additionally, the board approved a ₹5.50 crore investment in its subsidiary, Think Health Diagnostics, and proposed broadening its business scope through MOA amendments.
Key Highlights
Recommended final dividend of ₹7.00 per share; total FY26 dividend aggregates to ₹9.33 per share
Appointment of Price Waterhouse Chartered Accountants LLP as Statutory Auditors for a 5-year term (2026-2031)
Re-appointment of Rahul Franklin Guha as Chairman, MD & CEO for a 5-year term starting May 2027
Approved investment of up to ₹5.50 crore in wholly-owned subsidiary Think Health Diagnostics Private Limited
Proposed alteration of Memorandum of Association to broaden scope within the healthcare and diagnostics ecosystem
👀 What to Watch
Investors should take note of the strong dividend payout and the transition to a Big 4 audit firm, which enhances corporate governance. The leadership continuity and expansion into allied healthcare services provide a positive long-term outlook.
Thyrocare Recommends ₹7 Final Dividend, Re-appoints CEO & Approves ₹5.5 Cr Subsidiary Investment
Thyrocare Technologies has recommended a final dividend of ₹7.00 per share, bringing the total FY26 dividend to ₹9.33 per share post-bonus adjustment. The board approved the re-appointment of Rahul Franklin Guha as MD & CEO for a five-year term starting May 2027, ensuring leadership continuity. Strategically, the company is investing ₹5.50 crore in its subsidiary, Think Health Diagnostics, and broadening its Memorandum of Association to include a wider range of digital healthcare and diagnostic services. Significant board changes were also announced, including the appointment of two new directors and the resignation of two others.
Key Highlights
Recommended final dividend of ₹7.00 per equity share for FY 2025-26
Total FY26 dividend aggregates to ₹9.33 per share after post-bonus adjustment
Re-appointment of Rahul Franklin Guha as MD & CEO for a 5-year term until 2032
Approved investment of up to ₹5.50 crore in wholly owned subsidiary Think Health Diagnostics
Appointment of Price Waterhouse Chartered Accountants LLP as Statutory Auditors for 5 years
👀 What to Watch
Investors should take note of the healthy dividend payout and the continuity in top leadership as positive indicators. The expansion of the company's business scope via MOA changes suggests a strategic push into digital health platforms which warrants long-term monitoring.
Thyrocare Recommends ₹7 Final Dividend, Re-appoints CEO, and Invests ₹5.5 Cr in Subsidiary
Thyrocare's board has recommended a final dividend of ₹7.00 per share, bringing the total FY26 dividend to ₹9.33 per share post-bonus adjustment. The company approved a ₹5.50 crore investment in its wholly-owned subsidiary, Think Health Diagnostics, to strengthen its diagnostic footprint. Rahul Franklin Guha has been re-appointed as CMD and CEO for a five-year term starting May 2027, ensuring leadership continuity. Additionally, the board approved the appointment of Price Waterhouse Chartered Accountants LLP as statutory auditors for a five-year term.
Key Highlights
Recommended final dividend of ₹7.00 per equity share for FY 2025-26
Total dividend for FY26 aggregates to ₹9.33 per share post-bonus adjustment
Re-appointed Rahul Franklin Guha as CMD & CEO for a 5-year term until May 2032
Approved ₹5.50 crore investment in subsidiary Think Health Diagnostics Private Limited
Appointed Price Waterhouse Chartered Accountants LLP as Statutory Auditors for 5 years
👀 What to Watch
Investors should welcome the healthy dividend payout and the stability provided by the CEO's five-year re-appointment. The expansion of the Memorandum of Association and subsidiary investment suggest a strategic push into broader healthcare services.
Thyrocare Re-appoints CEO, Declares ₹7 Dividend, and Approves ₹5.5 Cr Subsidiary Investment
Thyrocare's board has recommended a final dividend of ₹7.00 per share, bringing the total FY26 dividend to ₹9.33 per share post-bonus adjustment. The company ensured leadership continuity by re-appointing Rahul Franklin Guha as Chairman, MD & CEO for a five-year term starting May 2027. Additionally, the board approved a ₹5.50 crore investment in its subsidiary, Think Health Diagnostics, to strengthen its diagnostic footprint. The company is also proposing to broaden its business scope through amendments to its Memorandum of Association to include a wider range of healthcare services.
Key Highlights
Recommended a final dividend of ₹7.00 per equity share for FY 2025-26.
Re-appointed Rahul Franklin Guha as Chairman, MD & CEO for a 5-year term starting May 4, 2027.
Approved an investment of up to ₹5.50 crore in wholly-owned subsidiary Think Health Diagnostics Private Limited.
Appointed Price Waterhouse Chartered Accountants LLP as Statutory Auditors for a five-year term.
Proposed broadening the Memorandum of Association to include allied healthcare and digital platform services.
👀 What to Watch
Investors should take note of the leadership stability and the healthy dividend yield. The expansion of business objects suggests a strategic move toward a more integrated healthcare ecosystem which warrants long-term monitoring.
Thyrocare Recommends ₹7 Final Dividend, Re-appoints CEO, and Plans ₹5.5 Cr Subsidiary Investment
Thyrocare Technologies has recommended a final dividend of ₹7.00 per equity share, bringing the total dividend for FY26 to ₹9.33 per share post-bonus adjustment. The board has approved the re-appointment of Rahul Franklin Guha as MD & CEO for a five-year term starting May 2027, ensuring leadership continuity. Additionally, the company will invest up to ₹5.50 crore in its wholly-owned subsidiary, Think Health Diagnostics, to expand its healthcare ecosystem. Significant board reshuffling and the appointment of Price Waterhouse as statutory auditors were also confirmed.
Key Highlights
Recommended final dividend of ₹7.00 per share; total FY26 dividend reaches ₹9.33 per share post-bonus adjustment
Re-appointment of Rahul Franklin Guha as Chairman, MD & CEO for a 5-year term (2027-2032)
Approved investment of up to ₹5.50 crore in wholly-owned subsidiary Think Health Diagnostics Private Limited
Appointment of Price Waterhouse Chartered Accountants LLP as Statutory Auditors for a 5-year term
Resignation of two Non-Executive Directors and appointment of Uday Patel Kadam and Gaurav Verma to the board
👀 What to Watch
Investors should find the dividend payout and leadership continuity encouraging for long-term stability. The expansion of the Memorandum of Association and subsidiary investment suggest a strategic push into broader diagnostic and digital healthcare services.
Thyrocare Recommends ₹7 Final Dividend, Re-appoints CEO, and Invests ₹5.5 Cr in Subsidiary
Thyrocare's board has recommended a final dividend of ₹7.00 per share, bringing the total FY26 dividend to ₹9.33 per share post-bonus adjustment. The company has re-appointed Rahul Franklin Guha as MD & CEO for a five-year term and approved a ₹5.50 crore investment in its subsidiary, Think Health Diagnostics. Significant board changes include the resignation of two directors and the appointment of two new non-executive directors. Additionally, the company is amending its Memorandum of Association to significantly broaden its scope in the healthcare and digital diagnostic ecosystem.
Key Highlights
Recommended final dividend of ₹7.00 per share; total FY26 dividend stands at ₹9.33 per share post-bonus adjustment.
Re-appointed Rahul Franklin Guha as Chairman, MD, and CEO for a 5-year term starting May 2027.
Approved ₹5.50 crore investment in wholly-owned subsidiary Think Health Diagnostics Private Limited.
Appointed Price Waterhouse Chartered Accountants LLP as Statutory Auditors for a 5-year term.
Proposed MOA changes to expand diagnostic activities into home collection, digital platforms, and allied healthcare services.
👀 What to Watch
Investors should find the consistent dividend payout and leadership continuity as positive indicators of corporate stability. The strategic expansion of the company's operational scope via MOA changes suggests a long-term growth plan in the digital healthcare space.
Thyrocare Recommends ₹7 Final Dividend; Total FY26 Dividend at ₹9.33 per Share
Thyrocare Technologies has recommended a final dividend of ₹7 per equity share for FY 2025-26, bringing the total dividend for the year to ₹9.33 per share post-bonus adjustment. The company also announced a ₹5.50 crore investment in its subsidiary, Think Health Diagnostics, to expand its diagnostic footprint. Significant leadership updates include the five-year re-appointment of Rahul Guha as CMD & CEO and the appointment of Price Waterhouse as Statutory Auditors. Furthermore, the company is amending its Memorandum of Association to broaden its scope in the healthcare and diagnostic ecosystem.
Key Highlights
Recommended final dividend of ₹7.00 per equity share for FY 2025-26
Total dividend for FY26 aggregates to ₹9.33 per share after post-bonus adjustment
Approved investment of up to ₹5.50 crore in wholly-owned subsidiary Think Health Diagnostics
Re-appointed Rahul Franklin Guha as CMD & CEO for a 5-year term starting May 2027
Appointed Price Waterhouse Chartered Accountants LLP as Statutory Auditors for a 5-year term
👀 What to Watch
Investors should view the consistent dividend payout and leadership continuity as positive signs of stability. The expansion of the company's business objects and investment in subsidiaries suggest a focus on long-term growth in the diagnostic sector.
Thyrocare Q4 FY26 Standalone Net Profit Surges 98.5% YoY to ₹43.58 Cr; Revenue Up 21%
Thyrocare Technologies reported a robust performance for the quarter ended March 31, 2026, with standalone revenue growing 21.2% YoY to ₹210.67 crore. Net profit for the quarter nearly doubled, rising 98.5% YoY to ₹43.58 crore, reflecting strong operational leverage. For the full financial year 2026, the company's net profit reached ₹148.81 crore, a significant 55.4% increase over the previous year's ₹95.78 crore. The company maintained an unmodified audit opinion, signaling healthy financial reporting standards.
Key Highlights
Standalone Revenue for Q4 FY26 rose 21.2% YoY to ₹210.67 crore from ₹173.87 crore.
Net Profit for Q4 FY26 jumped 98.5% YoY to ₹43.58 crore compared to ₹21.95 crore in the same period last year.
Full-year FY26 Net Profit increased by 55.4% to ₹148.81 crore against ₹95.78 crore in FY25.
Annual Revenue from operations grew 22.3% to ₹774.27 crore in FY26.
Basic EPS for the full year improved significantly to ₹9.36 from ₹5.98 in the previous fiscal year.
👀 What to Watch
The strong double-digit growth in revenue and substantial margin expansion leading to a profit surge are very positive indicators for the stock. Investors should consider the company's improved profitability and operational efficiency as a sign of strengthening market position in the diagnostic sector.
Religare Subsidiary Care Health's Tax Liability Reduced to ₹45.16 Cr via Rectification Order
Religare Enterprises' material subsidiary, Care Health Insurance Limited (CHIL), has received a rectification order from the Income Tax department for Assessment Year 2023-24. The order corrects a technical error in the initial demand, effectively reducing the net tax liability from ₹89.02 Crore to ₹45.16 Crore. While this reduction is a positive development, CHIL continues to contest the remaining additions through an appeal filed with the appropriate authorities. The financial impact of this subsidiary is consolidated into Religare's overall performance.
Key Highlights
Rectification order received under Section 154 of the Income-tax Act for AY 2023-24
Net tax liability reduced by approximately 49%, from ₹89.02 Crore to ₹45.16 Crore
The correction was issued to fix a technical error in the initial tax computation
CHIL has already filed an appeal against the original additions, which remains pending for adjudication
👀 What to Watch
Investors should view this as a positive development that reduces immediate financial pressure on the subsidiary. Monitor the outcome of the pending appeal for further potential reductions in tax liability.
Thyrocare Q4FY26 PAT Surges 128% YoY to ₹48.7 Cr; Revenue Up 20%
Thyrocare reported a strong Q4FY26 with consolidated revenue growing 20% YoY to ₹223.95 crore, driven by a 21% rise in the pathology segment. Profit After Tax (PAT) saw a massive jump of 128% YoY to ₹48.70 crore, while EBITDA margins improved to 34% from 31% in the previous year's quarter. For the full year FY26, the company achieved a revenue of ₹829.04 crore and a PAT of ₹162.85 crore, reflecting robust volume growth of 23%. The company is also diversifying into high-margin specialty diagnostics like genomics and allergy testing.
Key Highlights
Consolidated Q4FY26 revenue grew 20% YoY to ₹223.95 Cr, while FY26 revenue rose 21% to ₹829.04 Cr.
Q4FY26 PAT surged 128% YoY to ₹48.70 Cr; FY26 PAT grew 81% YoY to ₹162.85 Cr.
Test volumes increased by 29% YoY in Q4 to 59 million tests, maintaining industry volume leadership.
Reported EBITDA grew 31% YoY to ₹75.09 Cr in Q4, with margins expanding to 34%.
Expansion into specialty diagnostics with 250+ allergy SKUs and launch of Non-invasive Pre-Natal Testing (NIPT).
👀 What to Watch
Investors should view these results positively as the company demonstrates strong operating leverage and volume-led growth. The entry into high-value genomics and specialty testing provides a long-term catalyst for margin improvement.
Thyrocare Q4FY26 Results: PAT Surges 128% YoY to ₹49 Cr; EBITDA Margins Hit 34%
Thyrocare Technologies delivered a robust performance in Q4FY26, with consolidated revenue growing 20% YoY to ₹224 crore. The company saw a massive 128% jump in Profit After Tax (PAT) to ₹49 crore, aided by operational efficiencies and a 31% growth in EBITDA. For the full year FY26, revenue reached ₹829 crore (+21% YoY) with PAT rising 81% to ₹163 crore. The company successfully expanded its active franchisee network to a record 10,831 and increased its test menu by 39% to 1,275 offerings.
Key Highlights
Q4FY26 consolidated revenue grew 20% YoY to ₹224 crore, while FY26 revenue rose 21% to ₹829 crore.
Reported EBITDA margin improved to 34% in Q4FY26 compared to 31% in Q4FY25.
Full-year FY26 PAT stood at ₹162.8 crore, an 81% increase over the previous financial year.
The total number of tests conducted in FY26 reached 209.6 million, marking a 23% YoY growth.
Active franchisee count reached 10,831, reflecting a 15% YoY increase and a 25% CAGR since FY21.
👀 What to Watch
Investors should note the significant margin expansion and strong volume growth as signs of a successful operational turnaround. The company's focus on specialized tests and network expansion makes it a strong contender in the diagnostic space.
Religare Appoints Arjun Lamba as Executive Director for 5-Year Term
Religare Enterprises has received shareholder approval to appoint Mr. Arjun Lamba as a Whole Time Director (Executive Director) for a five-year term effective from April 01, 2026. Mr. Lamba, who has over 23 years of experience in Indian capital markets, was previously a Non-Executive Director and played a pivotal role in the Burman Family's acquisition of the company. This transition to an executive role signifies a more hands-on leadership approach by the major stakeholders. The appointment was confirmed following the voting results of the Extra Ordinary General Meeting held on May 05, 2026.
Key Highlights
Appointment of Mr. Arjun Lamba as Whole Time Director for a 5-year term starting April 01, 2026
Mr. Lamba brings over 23 years of experience in capital markets and is the founder of Guardian Advisors
Played a critical role in the Burman Family's acquisition of both Religare Enterprises and Eveready Industries
Holds board positions across key subsidiaries including Care Health Insurance and Religare Finvest
The appointment was approved by shareholders in the EGM held on May 05, 2026
👀 What to Watch
Investors should view this as a positive step towards leadership stability and a sign of the Burman group's commitment to the company's turnaround. Monitor the company's progress in resolving legacy regulatory issues under this strengthened executive leadership.
Thyrocare Recommends ₹7 Final Dividend, Re-appoints CEO, and Approves ₹5.5 Cr Subsidiary Investment
Thyrocare Technologies has recommended a final dividend of ₹7.00 per share for FY26, bringing the total annual dividend to ₹9.33 per share post-bonus adjustment. The board approved the re-appointment of Rahul Franklin Guha as MD & CEO for a five-year term starting May 2027, ensuring leadership continuity. A strategic investment of up to ₹5.50 crore was approved for its wholly-owned subsidiary, Think Health Diagnostics, to bolster its diagnostic footprint. Additionally, the company is broadening its Memorandum of Association to include a wider range of healthcare and allied services.
Key Highlights
Recommended a final dividend of ₹7.00 per share; total FY26 dividend aggregates to ₹9.33 per share.
Re-appointed Rahul Franklin Guha as Chairman, MD & CEO for a 5-year term (2027-2032).
Approved an investment of up to ₹5.50 crore in wholly-owned subsidiary Think Health Diagnostics Private Limited.
Appointed Price Waterhouse Chartered Accountants LLP as Statutory Auditors for a 5-year term.
Proposed broadening the Memorandum of Association to include allied healthcare services and equipment dealing.
👀 What to Watch
Investors should find confidence in the leadership continuity and the healthy dividend payout. The expansion of the business object clause suggests a strategic move toward a more integrated healthcare ecosystem which warrants long-term monitoring.
Religare Shareholders Approve Office Shift and Appointment of Arjun Lamba as Executive Director
Religare Enterprises Limited held an Extraordinary General Meeting (EGM) on May 05, 2026, where shareholders approved two key special resolutions. The first resolution to shift the company's registered office from Delhi to Haryana passed with a 98.48% majority. The second resolution, appointing Mr. Arjun Lamba as a Whole Time Director (Executive Director) and approving his remuneration, was passed with 95.53% support. While overall approval was high, institutional investors showed notable dissent on the director's appointment, with 21.13% of their votes cast against it.
Key Highlights
Resolution to shift registered office from Delhi to Haryana approved with 98.48% votes in favor.
Appointment of Mr. Arjun Lamba as Whole Time Director approved with 95.53% of total votes polled.
Institutional investors cast 21.13% of their votes against the appointment and remuneration of Mr. Lamba.
Total voter turnout for the EGM stood at 56.7% of the total outstanding shares.
A total of 18,87,47,494 votes were polled across 77,860 shareholders on record.
👀 What to Watch
Investors should note the successful management transition but remain aware of the significant institutional dissent (21%) regarding the new Executive Director's appointment. The office relocation is a routine administrative change and is unlikely to impact the stock's fundamental value.
Waaree Energies Unveils Unbound 2.0 Strategy Targeting 300GW+ India Solar Market by 2030
Waaree Energies has outlined its 'Unbound 2.0' roadmap, focusing on an integrated solar value chain and aggressive entry into the BESS and inverter segments. The company aims to capitalize on India's projected 341 GW cumulative solar capacity by FY30 and the global shift toward non-Chinese supply chains. A key project includes establishing India's first fully integrated battery cell-and-pack gigafactory, scheduled for significant milestones by April 2026. This strategic pivot positions Waaree as a comprehensive energy solutions provider, leveraging its existing 10 GW+ manufacturing ecosystem.
Key Highlights
Targeting India's solar installation growth to 341 GW cumulative capacity by FY30 from current levels.
Developing India's first fully integrated battery cell-and-pack gigafactory with a roadmap reaching April 2026.
Expanding inverter manufacturing range from 500W to 350kW to capture residential, C&I, and utility segments.
Leveraging a 10 GW+ manufacturing ecosystem to maintain a competitive CAPEX advantage over new entrants.
Positioning to capture US market demand for non-Chinese solar components amid ongoing geopolitical energy crises.
👀 What to Watch
Investors should monitor the timely execution of the BESS gigafactory and the market share gains in the inverter segment as these represent high-margin growth drivers. The company is well-positioned to benefit from the PM Surya Ghar scheme and global supply chain shifts.
R. S. Software Approves Audited FY26 Results with Unmodified Auditor Opinion
R. S. Software (India) Limited has approved its audited standalone and consolidated financial results for the quarter and full year ending March 31, 2026. The company's statutory auditors have issued an unmodified opinion, indicating that the financial statements present a true and fair view of the company's affairs. Additionally, the company confirmed it does not fall under the SEBI category of 'Large Corporate' for debt fundraising purposes. While the specific profit and loss figures were not detailed in the cover letter, the formal approval marks the completion of the annual audit cycle.
Key Highlights
Board approved audited standalone and consolidated financial results for the fiscal year ended March 31, 2026.
Statutory auditors issued an Unmodified Opinion on the financial results for the period.
Company confirmed non-applicability of SEBI framework for fund raising by issuance of debt securities by Large Corporates.
The Board meeting commenced at 11:30 AM and concluded at 13:50 PM on May 07, 2026.
Q4 FY26 figures were derived from the difference between audited full-year and published nine-month results.
👀 What to Watch
Investors should examine the detailed profit and loss statement and balance sheet once the full annexures are released to evaluate revenue and margin trends. The unmodified audit opinion provides comfort regarding the company's financial reporting integrity.
Waaree Renewable to Acquire 55% Stake in Associated Power Structures for Rs 1,225 Cr
Waaree Renewable Technologies Limited (WRTL) has executed definitive agreements to acquire a 55% majority stake in Associated Power Structures Private Limited (APSPL). The total investment for this acquisition is valued at Rs. 1,225 Cr, which will result in APSPL becoming a subsidiary of WRTL. Although the acquisition was originally slated for completion by April 30, 2026, the timeline has been extended to June 15, 2026, due to procedural requirements. The transaction involves both the purchase of existing shares from selling shareholders and a fresh subscription of equity.
Key Highlights
Acquisition of a 55% majority stake in Associated Power Structures Private Limited (APSPL) on a fully diluted basis.
Total investment value for the transaction is fixed at Rs. 1,225 Cr.
Execution of Shareholders Agreement (SHA) and Share Purchase and Subscription Agreement (SPSA) completed.
Completion timeline for the acquisition extended from April 30, 2026, to June 15, 2026.
APSPL will become a subsidiary of Waaree Renewable Technologies Limited upon completion.
👀 What to Watch
Investors should view this as a significant strategic expansion that strengthens the company's market position, though they should monitor the revised completion date of June 15, 2026.
Bajaj Healthcare Receives Listing Approval for 20.79 Lakh Equity Shares
Bajaj Healthcare Limited has received in-principle approval from both NSE and BSE for the listing of 20,79,409 equity shares of face value ₹5 each. These shares were allotted following the conversion of warrants previously issued on a preferential basis. The listing will proceed once the company receives confirmation of credit from the depositories (NSDL and CDSL). This move completes a stage of the company's capital raising process, increasing the total outstanding equity shares.
Key Highlights
Listing approval granted for 20,79,409 equity shares of ₹5 face value each
Shares issued pursuant to conversion of warrants on a preferential basis
In-principle approval received from both BSE Limited and National Stock Exchange of India
New shares carry distinctive numbers from 31583253 to 33662661
Trading to commence post confirmation of credit from NSDL/CDSL
👀 What to Watch
Investors should account for the slight dilution in Earnings Per Share (EPS) resulting from the increased share capital. No immediate action is required as this is a procedural step following a prior preferential allotment.
Waaree Energies Subsidiary Signs PPA for 300MW Wind Power Project in Gujarat
Waaree Energies Limited's step-down subsidiary, Waaree Forever Energies Four Private Limited, has executed a Power Purchase Agreement (PPA) with the Solar Energy Corporation of India Limited (SECI). The agreement is for the development of a 300MW Wind Power Project located in Dwarka, Gujarat. This formalizes the project following an initial intimation in February 2026, providing long-term revenue visibility for the company's renewable energy portfolio. The move signifies Waaree's growing footprint in the wind energy sector alongside its solar operations.
Key Highlights
Execution of PPA with SECI for a 300MW Wind Power Project
Project location identified as Dwarka, Gujarat
Agreement signed by wholly-owned step-down subsidiary Waaree Forever Energies Four Pvt Ltd
Follows up on the initial project announcement dated February 24, 2026
Strengthens long-term order book and renewable energy asset base
👀 What to Watch
Investors should view this as a positive development for long-term revenue stability and business diversification. Monitor the company's execution progress and any updates on the commissioning timeline for this 300MW capacity.
